Why the study?
Does FR168888 reduce ischemia and reperfusion-induced arrhythmia and myocardial infarction in rats compared to other cardioprotective compounds?
Population
Anesthetized rats (in vivo) and rat lymphocytes (in vitro)
Comparison
FR168888 (5-hydroxymethyl-3-benzoylguanidine… vs Lidocaine, propranolol and diltiazem
Design
Preclinical
Follow-up
Up to 60 minutes of reperfusion
Authors
Loading...
Hypothesis-generating for Na+/H+ inhibition in rat reperfusion injury; leaves open translation to clinical cardioprotection.
Does FR168888 reduce ischemia and reperfusion-induced arrhythmia and myocardial infarction in rats compared to other cardioprotective compounds?
FR168888, a novel Na+/H+ exchange inhibitor, demonstrates potent cardioprotective and antiarrhythmic effects in a rat model of ischemia-reperfusion injury.
Ohara et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: